Granulosa Cell Tumors
What is Granulosa Cell Tumors?
Granulosa cell tumors are rare growths that develop in the ovaries. They form in the cells that surround and support developing eggs. These tumors account for about 2 to 5 percent of all ovarian cancers.
Most granulosa cell tumors grow slowly and are found at an early stage. They produce hormones, especially estrogen and a protein called Anti-Mullerian Hormone. This hormone production can cause noticeable symptoms that lead to earlier detection. About 70 percent of these tumors are diagnosed at stage one, when the tumor is still contained within the ovary.
These tumors can occur at any age but fall into two types. Adult-type granulosa cell tumors typically appear after menopause, around age 50 to 55. Juvenile-type tumors are much rarer and usually develop before age 30. Both types require medical attention, but the adult type is far more common.
Symptoms
- Abnormal vaginal bleeding, including bleeding after menopause or irregular periods
- Abdominal swelling or a noticeable mass in the pelvis
- Pelvic pain or discomfort
- Early puberty in young girls with juvenile-type tumors
- Breast tenderness due to elevated estrogen levels
- Bloating or feeling full quickly when eating
- Changes in bowel or bladder habits
- Thickening of the uterine lining from excess estrogen
Some women with small tumors may have mild symptoms that are easy to overlook. The most common first sign is abnormal bleeding, which prompts many women to seek medical care. Early detection improves treatment outcomes significantly.
Concerned about Granulosa Cell Tumors? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
The exact cause of granulosa cell tumors remains unknown. They develop when cells in the ovary begin to grow abnormally and form a tumor. Unlike many cancers, these tumors are not strongly linked to inherited genetic mutations. Most cases occur randomly without a family history of the condition.
Risk factors include being over age 50 for the adult type. Conditions that affect ovarian function may play a role, but research is still limited. These tumors are not associated with lifestyle factors like diet or exercise. They produce excess hormones as they grow, which causes many of the symptoms women experience.
How it's diagnosed
Diagnosis typically starts with a pelvic exam and imaging tests. Ultrasound can reveal masses on the ovaries. CT or MRI scans help determine the size and spread of the tumor. Blood tests play a key role in confirming the diagnosis and monitoring treatment.
Anti-Mullerian Hormone testing is especially useful for granulosa cell tumors. These tumors produce high levels of AMH, which shows up in a simple blood test. Rite Aid offers AMH testing as an add-on to help detect and monitor this condition. Elevated AMH levels can indicate the presence of a tumor and help doctors track whether treatment is working. A biopsy of the tumor tissue provides the final diagnosis and determines the specific type.
Treatment options
- Surgery to remove the affected ovary and tumor is the primary treatment
- In early-stage disease, fertility-sparing surgery may be possible for younger women
- Chemotherapy for advanced-stage tumors or recurrence
- Radiation therapy in select cases where tumors have spread
- Regular monitoring with AMH blood tests to detect recurrence early
- Hormone therapy may be needed if both ovaries are removed
- Follow-up imaging and blood tests every 3 to 6 months initially
- Healthy lifestyle habits to support recovery and overall health
Need testing for Granulosa Cell Tumors? Add it to your panel.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
Granulosa cell tumors are rare growths that develop in the ovaries from cells that support egg development. They produce hormones like estrogen and Anti-Mullerian Hormone. These tumors grow slowly and are often found early because the excess hormones cause noticeable symptoms like abnormal bleeding.
Abnormal vaginal bleeding is the most common symptom, especially bleeding after menopause or irregular periods. Other symptoms include abdominal swelling, pelvic pain, and bloating. Some women notice breast tenderness from elevated estrogen levels produced by the tumor.
Doctors use pelvic exams, ultrasound, and CT or MRI scans to find ovarian masses. Blood tests measuring Anti-Mullerian Hormone levels help confirm the diagnosis since these tumors produce high amounts of AMH. A biopsy of tumor tissue provides the final diagnosis and determines the tumor type.
Yes, Anti-Mullerian Hormone blood tests can detect granulosa cell tumors. These tumors produce markedly elevated levels of AMH, which shows up in testing. AMH testing is also used to monitor treatment response and watch for tumor recurrence after treatment.
Most granulosa cell tumors are considered low-grade cancers that grow slowly. About 70 percent are found at stage one when still contained in the ovary. While they can spread or come back years later, early detection and treatment lead to good outcomes for most patients.
The exact cause is unknown, but these tumors develop when ovarian cells begin growing abnormally. They are not strongly linked to inherited genes or family history. Unlike many cancers, lifestyle factors like diet and exercise do not appear to increase risk.
Surgery to remove the affected ovary and tumor is the main treatment. Younger women who want to preserve fertility may have only the affected ovary removed if the tumor is caught early. Advanced-stage tumors may require chemotherapy, and regular AMH testing helps monitor for recurrence.
Yes, granulosa cell tumors can recur even years after successful treatment. This is why regular monitoring is essential. Blood tests measuring AMH levels help detect recurrence early, often before symptoms appear. Most recurrences happen within 5 to 10 years but can occur later.
Adult-type granulosa cell tumors typically affect women over age 50, especially after menopause. Juvenile-type tumors are rare and usually develop in young girls or women under 30. There are no known strong risk factors, and most cases occur randomly without family history.
After treatment, doctors typically recommend AMH blood tests and imaging every 3 to 6 months for the first few years. Testing frequency may decrease over time based on your individual risk. Regular monitoring is important because these tumors can return years after initial treatment.